TriSalus Life Sciences Inc
For the period ended Dec 31, 2023. Filed Apr 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 11, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| 2023 | 2022 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(59,038) | $(47,187) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 702 | 398 |
| Loss on equity issuance | 4,353 | 8,312 |
| Change in fair value of tranche and warrant liabilities | 10,855 | 2,186 |
| Change in fair value of contingent earnout liabilities | (10,293) | — |
| Share-based compensation expense | 1,402 | 368 |
| Loss on disposal of fixed assets | 44 | 310 |
| Loss on impairment of intangible assets | 190 | — |
| Milestone payment to Dynavax | 1,000 | 1,000 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,979) | (200) |
| Inventory | (1,073) | (179) |
| Prepaid expenses | 1,032 | (2,592) |
| Operating lease right-of-use assets | 202 | 112 |
| Operating lease liabilities | (281) | (87) |
| Trade payables, accrued expenses and other liabilities | 2,839 | 5,246 |
| Net cash used in operating activities | (50,045) | (32,313) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (588) | (655) |
| Milestone payment to Dynavax | (1,000) | (1,000) |
| Cash paid for intellectual property and licenses | (533) | (131) |
| Net cash used in investing activities | (2,121) | (1,786) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of preferred stock, net of costs of $0 and $242, in the years ended December 31, 2023 and 2022, respectively | 9,189 | 13,499 |
| Proceeds from exercise of preferred stock warrants | 9,630 | — |
| Purchase of common stock warrants | (20) | — |
| Proceeds from Business Combination | 36,854 | — |
| Offering costs related to Business Combination | (1,116) | — |
| Payments on finance lease liabilities | (87) | (131) |
| Cash proceeds from the exercise of stock options for common stock | 179 | 94 |
| Net cash provided by financing activities | 54,629 | 13,462 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 2,463 | (20,637) |
| Cash, cash equivalents and restricted cash, beginning of period | 9,664 | 30,301 |
| Cash, cash equivalents and restricted cash, end of period | $12,127 | $9,664 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid during the year for: | ||
| Income taxes | 14 | 9 |
| Supplemental disclosure of noncash items: | ||
| Fixed asset purchases included in trade payables and accrued expenses | 19 | 12 |
| Transfer of warrant liability to preferred stock upon exercise of warrants | 25,409 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.